Cary Adams on World Cancer Day and COVID-19’s Impact on Cancer Care

Video

CancerNetwork® spoke with the CEO of the Union for International Cancer Control to learn more about their efforts in oncology amidst the COVID-19 pandemic, and the work they are doing on World Cancer Day.

For World Cancer Day, the Union for International Cancer Control (UICC) is focusing its efforts on the nurses, doctors, researchers, volunteers, advocates, and other caregivers in oncology who are fighting the coronavirus disease 2019 (COVID-19) pandemic. The UICC’s “I Am and I Will” theme allows them to shine a light on those caregivers and the stories they tell.

“COVID-19 has impacted cancer control globally and the response by the cancer community has been extraordinary, heroic even,” said Dr. Cary Adams, CEO of UICC, in a press release. “This year, more than ever, it is appropriate that we celebrate their achievements on World Cancer Day. Let us all aim in 2021 to refocus our collective efforts on the long-term challenges that cancer poses to every country in the world. We must prevent more, diagnose earlier, and ensure that all people living with cancer have access to the quality treatment they need.”

In an interview with CancerNetwork®, Adams discussed research that UICC conducted, and the continuing efforts needed to combat COVID-19 in cancer care.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences™ Medical World News®, airing daily on all MJH Life Sciences™ channels.

Reference:

Adaptations and innovations in cancer care through COVID-19 and beyond. News release. Union for International Cancer Control. Published January 19, 2021. Accessed February 4, 2021. https://www.worldcancerday.org/world-cancer-day-2021-official-global-press-release.

Recent Videos
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
The Together for Supportive Cancer Care coalition may advance the national conversation in ensuring comprehensive care for all patients with cancer.
Health care organizations have come together to form the Together for Supportive Cancer Care coalition to address gaps in supportive cancer care services.
Further optimizing a PROTAC that targets MDM2 may lead to human clinical trials among patients with cancer harboring p53 mutations.
Subsequent testing among patients in a prospective study may affirm the ability of cfDNA sequencing to detect cancers in those with Li-Fraumeni syndrome.
cfDNA sequencing may allow for more accessible, frequent, and sensitive testing compared with standard surveillance in Li-Fraumeni syndrome.
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.